Its immunohistochemical markers include estrogen/progestin (ER/PR) and human epidermal growth factor receptor 2 (HER2), and breast cancer is divided into three main subtypes: ER/PR-positive, HER two-positive, and triple-negative breast cancer (TNBC) (Harbeck and Gnant, 2017). Here, ERBB2 is linked to triple-negative breast carcinoma.